Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVernalis PLC Share News (VER)

  • There is currently no data for VER

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK BROKER RATINGS: Shore Capital Upgrades Carnival To Buy

Mon, 15th Sep 2014 08:31

LONDON (Alliance News) - The following UK shares received analyst recommendations Monday morning:
----------
FTSE 100
----------
TRADERS: SHORE CAPITAL RAISES CARNIVAL TO 'BUY' ('HOLD')
----------
BERNSTEIN CUTS PETROFAC PRICE TARGET TO 1,400 (1,500) PENCE - 'OUTPERFORM'
----------
DEUTSCHE BANK CUTS GLAXOSMITHKLINE PRICE TARGET TO 1450 (1500) PENCE - 'HOLD'
----------
JPMORGAN CUTS GLAXOSMITHKLINE PRICE TARGET TO 1350 (1370) PENCE - 'NEUTRAL'
----------
NUMIS RAISES FRESNILLO PRICE TARGET TO 1250 (1150) PENCE - 'BUY'
----------
FTSE 250
----------
BERENBERG CUTS ASHMORE GROUP PRICE TARGET TO 325 (335) PENCE - 'HOLD'
----------
CITIGROUP CUTS ASHMORE GROUP PRICE TARGET TO 350 (360) PENCE - 'NEUTRAL'
----------
BERENBERG RAISES NORTHGATE PRICE TARGET TO 660 (650) PENCE - 'BUY
----------
GOLDMAN RAISES HUNTING PRICE TARGET TO 910 (900) PENCE - 'NEUTRAL'
----------
BERNSTEIN INITIATES AMLIN WITH 'MARKET-PERFORM' - TARGET 415 PENCE
----------
BERNSTEIN INITIATES BEAZLEY GROUP WITH 'OUTPERFORM' - TARGET 305 PENCE
----------
BERNSTEIN INITIATES CATLIN GROUP WITH 'OUTPERFORM' - TARGET 625 PENCE
----------
BERNSTEIN INITIATES HISCOX WITH 'MARKET-PERFORM' - TARGET 690 PENCE
----------
TRADERS: SOCGEN CUTS AVEVA GROUP PRICE TARGET TO 2,250 (2,650) PENCE - 'BUY'
----------
LIBERUM CUTS AVEVA GROUP PRICE TARGET TO 1500 (2000) PENCE - 'HOLD'
----------
MAIN MARKET AND AIM
----------
GOLDMAN RAISES SPEEDY HIRE PRICE TARGET TO 68 (62) PENCE - 'NEUTRAL'
----------
TRADERS: INVESTEC CUTS HILTON FOOD PRICE TARGET TO 464 (501) PENCE - 'BUY'
----------
TRADERS: UBS CUTS STHREE PRICE TARGET TO 415 (440) PENCE
----------
LIBERUM RAISES PURECIRCLE PRICE TARGET TO 650 (600) PENCE - 'HOLD'
----------
SHORE CAPITAL RAISES GREGGS TO 'BUY' ('HOLD') - TARGET 536 PENCE
----------
CANACCORD RAISES VERNALIS PLC PRICE TARGET TO 56 (54) PENCE - 'BUY'
----------
CANACCORD RAISES TELIT COMMUNICATIONS PRICE TARGET TO 325 (305) PENCE - 'BUY'
----------
By Arvind Bhunjun; arvindbhunjun@alliancenews.com; @ArvindBhunjun

Copyright 2014 Alliance News Limited. All Rights Reserved.

More News
26 Apr 2016 11:38

UPDATE: Backed By CEO And Investors, Vernalis Raises GBP40 Million (ALLISS)

Read more
26 Apr 2016 10:22

Vernalis Eyes US Cough Cold Market With GBP40 Million Fundraising (ALLISS)

Read more
21 Apr 2016 14:44

Vernalis hires AstraZeneca marketeer to lead Tuzistra operation in US

(ShareCast News) - Vernalis has appointed 24-year AstraZeneca veteran Sandford 'Sandy' Sommer as president and chief operating officer of its US operation, Vernalis Therapeutics. Sommer most recent role was as president of AstraZeneca's Colombia operations, following a variety of leadership roles, i

Read more
21 Apr 2016 13:30

Vernalis Taps AstraZeneca Veteran Sommer For US Business

Read more
14 Apr 2016 08:06

Vernalis Says CCP-07 Study Completed, On Track For Application

Read more
13 Apr 2016 07:43

Vernalis Completes Single-Dose Study For Cough And Cold Product

Read more
17 Mar 2016 12:12

Vernalis drops into red after investment in cough treatment

(ShareCast News) - Shares in Vernalis sank to an 11-month low after the biotech company posted a half-year loss as its first prescription cough cold product, Tuzistra XR, launched during what has proved a very mild flu season in the USA. Revenue was up 7% to £6.1m in the six months to 31 December, b

Read more
17 Mar 2016 10:54

Vernalis Interim Loss Widens As Spending Rises On Launch Of Tuzistra

Read more
10 Mar 2016 16:07

Earnings, Trading Statements Calendar - Week Ahead

Read more
6 Jan 2016 08:40

Vernalis Reveals US-Based Corvus Pharmaceuticals As Licensee

Read more
21 Dec 2015 11:21

Vernalis Says Cough Cold Drug CCP-07 Completes Single-Dose Study

Read more
2 Dec 2015 10:37

Vernalis Confident After Tuzistra Launch And Moxatag Acquisition

Read more
25 Nov 2015 16:14

AGM, EGM Calendar - Week Ahead

Read more
12 Oct 2015 09:58

Vernalis Says Tris Pharma Begins Stability Testing Of CCP-08

Read more
2 Oct 2015 16:31

Vernalis acquires rights to Pragma's MOXATAG treatment

(ShareCast News) - Pharmaceutical group Vernalis has completed the acquisition of the US rights to the amoxicillin extended-release tablet brand MOXATAG from Pragma Pharmaceuticals. The London-listed company said it has made an undisclosed up-front payment in cash for the rights, with a further paym

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.